Béa Fertility raises $3.2m to launch at-home fertility treatment
Béa Fertility, a London-based fertility tech startup, has recently secured $3.2m in funding, bringing their total funding to $4.2m. The funding round was led by Octopus Ventures, accompanied by JamJar and Forward Partners, as well as existing investors Calm/Storm and Q Ventures. This financial support will enable the company to release their first at-home fertility treatment to early adopters in the UK.
With a team composed of femtech expert Tess Cosad and product engineer George Thomas at the helm, Béa Fertility has developed a clinical-grade at-home fertility kit that empowers users to safely carry out a treatment called Intracervical Insemination (ICI) in the comfort of their own homes.
The innovative Béa Treatment involves the use of a small cervical cap containing semen, which is applied to the cervix using a clinically-approved applicator. The cap remains in place for about an hour, allowing users to continue with their daily activities. After two weeks, users can perform a pregnancy test to determine the outcome of the treatment. Notably, the Béa Treatment eliminates the need for invasive hormone injections or clinical procedures and can be used with donor semen.
The Béa Treatment is now available for purchase on Béa's website, offering individuals the opportunity to take control of their fertility journey. Additionally, Béa Fertility is embarking on a pioneering pilot program in collaboration with South Fulham Primary Care Network. This initiative aims to trial the use of the Béa Treatment Kit within the NHS, providing direct access to fertility treatment in primary care. By making fertility care more accessible and convenient, Béa Fertility is revolutionizing how individuals can approach their reproductive health.
They've invested in Béa Fertility
Get to know these Healthtech investors
Click here for a full list of 6,528+ startup investors in the UK